Chiron Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.6M Buy
+191,288
New +$11.2M 11.89% 1
2025
Q3
$12.8M Sell
283,373
-3,040
-1% -$142K 10.94% 1
2025
Q2
$13.3M Sell
286,413
-13,195
-4% -$648K 11.54% 1
2025
Q1
$18.3M Sell
299,608
-109,920
-27% -$6.41M 16.61% 1
2024
Q4
$23.2M Sell
409,528
-35,078
-8% -$1.96M 21.86% 1
2024
Q3
$23M Sell
444,606
-7,778
-2% -$365K 20.36% 1
2024
Q2
$18.8M Buy
452,384
+5,664
+1% +$253K 17.94% 1
2024
Q1
$24.2M Buy
446,720
+2,105
+0.5% +$107K 22% 1
2023
Q4
$22.8M Sell
444,615
-25,095
-5% -$1.32M 19.85% 1
2023
Q3
$27.3M Sell
469,710
-8,963
-2% -$549K 23.45% 1
2023
Q2
$30.6M Buy
478,673
+1,538
+0.3% +$103K 24.24% 1
2023
Q1
$33.1M Sell
477,135
-9,013
-2% -$636K 22.99% 1
2022
Q4
$35M Sell
486,148
-35,991
-7% -$2.71M 24.33% 1
2022
Q3
$37.1M Sell
522,139
-15,058
-3% -$1.09M 24.94% 1
2022
Q2
$41.4M Sell
537,197
-80,823
-13% -$6.16M 26.09% 1
2022
Q1
$45.1M Sell
618,020
-95,696
-13% -$6.43M 28.45% 1
2021
Q4
$44.5M Sell
713,716
-370
-0.1% -$21.7K 32.12% 1
2021
Q3
$42.3M Buy
714,086
+50,004
+8% +$3.29M 30.82% 1
2021
Q2
$44.4M Sell
664,082
-100,971
-13% -$6.58M 36.97% 1
2021
Q1
$48.3M Sell
765,053
-7,414
-1% -$461K 40.99% 1
2020
Q4
$47.9M Sell
772,467
-11,612
-1% -$714K 39.45% 1
2020
Q3
$47.3M Buy
+784,079
New +$47.2M 38.07% 1

Other funds holding BMY

Chiron Capital Management's BMY Position: Q1 2026 in Review

Chiron Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 191,288 shares worth $11.6M. The stake represents 11.89% of the portfolio and ranks #1 among its holdings. This is a return to the name: Chiron Capital Management previously reported a position in BMY as recently as Q3 2025.

Chiron Capital Management first reported a position in BMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $48.3M in Q1 2021. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Chiron Capital Management held 191,288 shares of Bristol-Myers Squibb worth $11.6M as of Q1 2026.
  • Bristol-Myers Squibb was a new Chiron Capital Management position in Q1 2026.
  • Bristol-Myers Squibb made up 11.89% of Chiron Capital Management's portfolio in Q1 2026, its #1 holding.
  • Chiron Capital Management first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 22 quarters since.
  • Chiron Capital Management's Bristol-Myers Squibb position peaked at $48.3M in Q1 2021.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Chiron Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.